Skip to main content

Advertisement

SpringerLink
Log in

Avidity of onconeural antibodies is of clinical relevance

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Onconeural antibodies are important in the detection of paraneoplastic neurological syndromes (PNS). The avidity of Hu, Yo, and CRMP5 antibodies from 100 patients was determined by immunoprecipitation (IP), and 13 of the Yo positive sera were also tested by surface plasmon resonance (SPR). There was a significant association between the results from IP and SPR. Yo antibodies had higher avidity than Hu and CRMP5 antibodies, and both high- and low-avidity antibodies were associated with tumors and PNS. High-avidity Yo antibodies were mainly associated with ovarian cancer, whereas high-avidity Hu and CRMP5 antibodies were mainly associated with small-cell lung cancer. Low-avidity CRMP5 and Yo antibodies were less often detected by a commercial line blot than high-avidity antibodies. The failure to detect low-avidity onconeural antibodies may result in under diagnosis of PNS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554

    Article  PubMed  CAS  Google Scholar 

  2. Storstein A, Vedeler CA (2007) Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Adv Clin Chem 44:143–185

    Article  PubMed  CAS  Google Scholar 

  3. Pittock SJ, Kryzer TJ, Lennon VA (2004) Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56:715–719

    Article  PubMed  CAS  Google Scholar 

  4. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140

    Article  PubMed  CAS  Google Scholar 

  5. de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P (2012) Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71:815–824

    Article  PubMed  Google Scholar 

  6. Totland C, Aarseth J, Vedeler C (2007) Hu and Yo antibodies have heterogeneous avidity. J Neuroimmunol 185:162–167

    Article  PubMed  CAS  Google Scholar 

  7. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B (2004) High avidity anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 63:1478–1482

    Article  PubMed  CAS  Google Scholar 

  8. Comin R, Yuki N, Lopez PH, Nores GA (2006) High affinity of anti-GM1 antibodies is associated with disease onset in experimental neuropathy. J Neurosci Res 84:1085–1090

    Article  PubMed  CAS  Google Scholar 

  9. Leite MI, Waters P, Vincent A (2010) Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 43:371–379

    Article  PubMed  Google Scholar 

  10. Storstein A, Monstad SE, Haugen M, Mazengia K, Veltman D, Lohndal E, Aarseth J, Vedeler C (2011) Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol 232:166–1670

    Article  PubMed  CAS  Google Scholar 

  11. Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA (2004) Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 22:795–800

    Article  PubMed  CAS  Google Scholar 

  12. Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144:53–58

    Article  PubMed  CAS  Google Scholar 

  13. Monstad SE, Drivsholm L, Skeie GO, Aarseth JH, Vedeler CA (2008) CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother 57:227–232

    Article  PubMed  CAS  Google Scholar 

  14. Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA (2009) Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 58:1795–1800

    Article  PubMed  CAS  Google Scholar 

  15. Hedman K, Rousseau SA (1989) Measurement of avidity of specific IgG for verification of recent primary rubella. J Med Virol 27:288–292

    Article  PubMed  CAS  Google Scholar 

  16. Hutsell SQ, Kimple RJ, Siderovski DP, Willard FS, Kimple AJ (2010) High affinity immobilization of proteins using biotin- and GST-based coupling strategies. Methods Mol Biol 627:75–90

    Article  PubMed  CAS  Google Scholar 

  17. Jönsson U, Fägerstam L, Ivarsson B, Johnsson B, Karlsson R, Lundh K, Löfås S, Persson B, Roos H, Rönnberg I (1991) Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 11:620–627

    PubMed  Google Scholar 

  18. McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA (2011) Purkinje cell cytoplasmic autoantibody type 1 accompaniments. Arch Neurol 68:1282–1289

    Article  PubMed  Google Scholar 

  19. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG (2010) Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol 69:997–1007

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The study was supported by grants from the Western Norway Regional Health Authority and from the KG Jebsen Foundation for medical research.

Conflict of interest

The authors declare that they have no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway

    Cecilie Totland, Mette Haugen, Anette Storstein, Jan Aarseth & Christian Vedeler

  2. Department of Biomedicine, University of Bergen, Bergen, Norway

    Ming Ying & Aurora Martinez

  3. Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Kibret Mazengia & Christian Vedeler

Authors
  1. Cecilie Totland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mette Haugen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kibret Mazengia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anette Storstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan Aarseth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aurora Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian Vedeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Vedeler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Totland, C., Ying, M., Haugen, M. et al. Avidity of onconeural antibodies is of clinical relevance. Cancer Immunol Immunother 62, 1393–1396 (2013). https://doi.org/10.1007/s00262-013-1442-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-013-1442-6

Keywords

Search

Navigation